Frontera Therapeutics
PrivateLast Round
Series B
Jul 19, 2022
Total Funding Raised
$230M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Frontera Therapeutics is a biotechnology company that develops and commercializes recombinant adeno-associated virus (rAAV) gene therapies for the treatment of genetic disorders in ophthalmology, cardiology, and neurology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Frontera Therapeutics Comparables
Compare Frontera Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Exegenesis Bio | 86% | |
| Belief BioMed Inc. | 83% | |
| Avirmax, Inc. | 80% |
Frontera Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 19, 2022 |
Frontera Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boyu Capital | Series B |
| Creacion Ventures | Series B, Series A |
| Starr Investment Holdings | Series B |
| OrbiMed | Series B, Series A |
| Starr Investments & Benefits | Series B |
| TMCP | Series B |
| HongShan Capital Group (HSG) | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 51% MoM.
- Apr 22, 2025
Will present gene therapy advances at the 2025 ASGCT Annual meeting.
Frontera Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Frontera Therapeutics's valuation, stock price, and market status.
Is Frontera Therapeutics a public or private company?
Frontera Therapeutics is a private company.
What is the current stock price of Frontera Therapeutics?
Frontera Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Frontera Therapeutics worth (valuation)?
Valuation information for Frontera Therapeutics is not publicly available.
Can I buy Frontera Therapeutics stock?
Frontera Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Frontera Therapeutics's last funding round?
Frontera Therapeutics's most recent funding round was Series B on July 19, 2022.
Who are the main investors in Frontera Therapeutics?
Key investors in Frontera Therapeutics include Boyu Capital, Creacion Ventures, OrbiMed, HongShan.
Will Frontera Therapeutics IPO soon?
No public IPO plans have been announced for Frontera Therapeutics.
How can I track Frontera Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Frontera Therapeutics's secondary market activity and sign up for updates.